As of July 2025, Wegovy has stronger clinical evidence for supporting heart health. While both medications are primarily used for weight management, their impact on the cardiovascular system is a key area of medical research.
Use this guide to understand:
The specific heart health benefits of Wegovy.
The current state of research for Mounjaro.
How these medications are licensed in the UK.
Wegovy and cardiovascular risk reduction
A major clinical trial demonstrated that Wegovy could significantly protect the heart. The study showed that it could reduce the risk of serious heart problems—such as heart attacks or strokes—by 20% in adults with obesity and existing heart disease.
Because of these clear results, Wegovy is officially licensed in the UK for use in people with heart disease to help reduce cardiovascular risks.
Mounjaro and emerging research
While Mounjaro has shown excellent results for weight loss and blood sugar control, specific research into its long-term heart health benefits is still emerging.
It is expected that Mounjaro may offer similar cardiovascular protection, but until the full data from dedicated trials is available, Wegovy remains the treatment with the most established evidence in this specific area.
Choosing the right treatment
If you have a history of heart disease or are concerned about cardiovascular health, this evidence may be an important factor in your choice of treatment. Our clinical team can discuss these benefits with you during your consultation to ensure your treatment plan aligns with your overall health needs.
Need further support?
If you still need help after reviewing the information above, additional assistance is available.